U
PACB icon

UBS’s Pacific Biosciences PACB Stock Holding History

UBS’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$27K Buy
5,643
+3,343
+145% +$17.5K ﹤0.01% 7621
2014
Q2 		$14K Hold
2,300
– – ﹤0.01% 8525
2014
Q1 		$12K Buy
2,300
+1,500
+188% +$9.48K ﹤0.01% 8697
2013
Q4 		$4K Hold
800
– – ﹤0.01% 9716
2013
Q3 		$4K Hold
800
– – ﹤0.01% 9584
2013
Q2 		$2K Buy
+800
New +$1.99K ﹤0.01% 9817

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's PACB Position: Q3 2014 in Review

UBS increased its Pacific Biosciences (PACB) stake by 145% in Q3 2014, buying an estimated $17.5K and bringing the position to 5,643 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #7621.

UBS first reported a position in PACB in Q2 2013 and has held it in 6 quarters since. 88 funds tracked by Wall St. Rank hold PACB as of Q3 2014.

  • UBS held 5,643 shares of Pacific Biosciences worth $27K as of Q3 2014.
  • UBS bought 3,343 Pacific Biosciences shares in Q3 2014, an estimated $17.5K.
  • Pacific Biosciences made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7621 holding.
  • UBS first reported a position in Pacific Biosciences in Q2 2013 and has held it in 6 quarters since.
  • 88 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.